Alnylam reports new 12-month interim data from the envision phase 3 study of givosiran in acute hepatic porphyria

Alnylam reports new 12-month interim data from the envision phase 3 study of givosiran in acute hepatic porphyria.alnylam pharmaceuticals inc - safety profile consistent with that observed in 6-month double-blind period, with no new safety findings.alnylam pharmaceuticals inc - long-term givosiran dosing showed sustained reduction in annualized rate of composite porphyria attacks.
ALNY Ratings Summary
ALNY Quant Ranking